Table 4 Treatment and clinical outcomes
No Match | Match | |||||||
|---|---|---|---|---|---|---|---|---|
Total population n= 505 | Rivaroxaban n= 220 | Warfarin n= 285 | p value | Total population n= 418 | Rivaroxaban n= 209 | Warfarin n= 209 | p value | |
Admission to ICU, n(%) | 58 (11.5) | 21 (9.5) | 37 (13) | 0.23 | 37 (8.9) | 20 (9.6) | 17 (8.1) | 0.61 |
Need for IMV, n(%) | 13 (2.6) | 5 (2.3) | 8 (2.8) | 0.71 | 8 (1.9) | 4 (1.9) | 4 (1.9) | 1.00 |
Need for thrombolysis, n(%) | 15 (3) | 4 (1.8) | 11 (3.9) | 0.18 | 6 (1.4) | 4 (1.9) | 2 (1) | 0.41 |
Hospital stay days, m(SD) | 8.5 (14.33) | 7.4 (12.82) | 9.3 (15.37) | 0.13 | 7.8 (10.95) | 7.4 (13.08) | 8.2 (8.32) | 0.50 |
Initial treatment with enoxaparin, n(%) | 449 (88.9) | 176 (80) | 273 (95.8) | <0.01 | 367 (87.8) | 166 (79.4) | 201 (96.2) | <0.01 |
Major bleeding at 12 months, n(%) | 35 (6.9) | 6 (2.7) | 29 (10.2) | 0.01 | 29 (6.9) | 6 (2.9) | 23 (11) | 0.01 |
New episode of VTE | 30 (5.9) | 12 (5.5) | 18 (6.3) | 0.68 | 27 (6.5) | 12 (5.7) | 15 (7.2) | 0.55 |